Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
Journal Title: Chinese Journal of Clinical Research - Year 2025, Vol 38, Issue 1
Abstract
"<b>Objective</b> To analyze the clinical efficacy and the occurrence of adverse events of the oxaliplatin and capecitabine (XELOX) combined with sintilimab as a first-line treatment in patients with human epidermal growth factor receptor2 (HER2)-negative advanced gastric cancer(GC). <b>Methods</b> Eighty patients with HER2-negative GC admitted to the Affiliated Hospital of Xuzhou Medical University between February 2021 and December 2022 were prospectively selected. Patients were randomly assigned to the observation group and the control group, with 40 cases in each group. The control group was treated with XELOX regimen alone, and the observation group was treated with XELOX plus sintilimab. The clinical efficacy, progression-free survival (PFS), and incidence of adverse events were compared between the two groups. <b>Results</b> After three treatment cycles, the objective response rate (ORR) and disease control rate (DCR) in the observation group were higher than those in the control group (62.50%vs 40.00%,χ2 =4.053,P <0.05; 95.00%vs 72.50%,χ2=7.440,P <0.01）. The median PFS (mPFS) was 232.5 days in the observation group, compared to 154 days in the control group, showing a statistically significant improvement (P<0.05). Among programmed cell death ligand-1 (PD-L1) high-expression patients, the efficacy in the observation group was significantly superior to that in patients with PD-L1 low-expression (P <0.05). Additionally, the efficacy of PD-L1 low-expression patients in the observation group was higher than that of PD-L1 low-expression patients in the control group (Z =2.347,P <0.05). The incidence of treatment-related adverse events was not significantly different between the two groups (P >0.05). <b>Conclusion</b> The combination of XELOX and sintilimab demonstrates superior clinical efficacy and manageable safety in patients with HER2-negative advanced GC compared to XELOX alone. The regimen is particularly effective in improving the prognosis of patients with high PD-L1 expression."
Authors and Affiliations
ZHANG Xiaorui, SHAN Haixia, ZHU Zhengqiu
Keywords
Related Articles
- EP ID EP759889
- DOI -
- Views 12
- Downloads 0
Personalized anticoagulant therapy strategies for deep vein thrombosis
Deep vein thrombosis (DVT) is a common vascular condition that can lead to severe complications such as pulmonary embolism and chronic post-thrombotic syndrome. Anticoagulant therapy is the cornerstone of DVT management....
Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma
<b>Objective</b> To investigate the expression of programmed cell death protein 1(PD-1), programmed cell death 1 ligand 1 (PD-L1) and tumor infiltrates lymphocytes (TIL) density in neuroblastoma and the relationship betw...
Predictive value of dynamic assessment of thrombose-related factors in diabetic nephropathy patients for thrombotic risk
"<b>Methods</b> A retrospective study was conducted to select 98 patients with DN who were treated in Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2020 to September 2022. Follow-u...
Correlation between skeletal muscle mass and islet function in patients with type 2 diabetes mellitus
"<b>Objective</b> To investigate the correlation between skeletal muscle mass and islet function, skeletal muscle mass and insulin resistance in patients with type 2 diabetes mellitus (T2DM), and to elaborate on the clin...
Application of peripheral nerve invasion based nomogram model in predicting the prognosis of stage Ⅰ-Ⅲ early-onset colorectal cancer
Objective To evaluate the impact of peripheral nerve aggression (PNI) on prognosis in patients with stage Ⅰ-Ⅲ early-onset colorectal cancer (EO-CRC) and to create a PNI-based nomogram prediction model. Methods This study...